Biovac and partners to expand vaccine manufacturing capacity for Africa

1 March 2022

south_africa_cape_town_shutterstock_large

South African biopharma Biovac has teamed up with a consortium of nine development partners to expand the firm’s vaccine manufacturing plant capacity, and enable the production of the Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) COVID-19 jab and other vaccines.

Biovac will also raise around $150 million to boost increased local vaccine manufacturing capacity across the African continent, helping to reduce reliance on imports.

"The consortium of funders is willing to work with Biovac to create sustainable African vaccine manufacturing"Partners from the consortium include the African Development Bank, CDC Group – the UK’s development finance institution which is soon to be renamed British International Investment, German development finance institution DEG and the US International Development Finance Corporation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK